Help

Search Results

38 results

  1. TSRC, Tob. Sci. Res. Conf., 2022, 75, abstr. 12

    Development of modified risk claims and supportive language to motivate and inform adult smokers to switch from cigarettes to an oral tobacco-derived nicotine product

    KARELITZ J.; LEIGHTY J.; BECKER E.; SARKAR M.
    Altria Client Services, Richmond, VA, USA
    Cigarettes are the most harmful of all tobacco products, whereas smoke-free products are on the lower end of the risk continuum. Adult smokers (AS), particularly those unable or unwilling to quit smoking, may reduce their risks of smoking-related...
  2. TSRC, Tob. Sci. Res. Conf., 2022, 75, abstr. 136

    Consumer-reported outcome measure (CROM) guidelines with respect to descriptive-CROM for research on tobacco and nicotine-containing products

    WEI Lai(1) on behalf of the CROM Task Force: SARKAR M.(1); CLERC E.(2); CHREA C.(2); SHETTY M.(3); PRASAD K.(3); KIM M.(4); GOLDENSON N.(5)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) British American Tobacco, Southampton, UK; (4) RAI Services Company, Winston-Salem, NC, USA; (5) Juul Labs, Washington, DC, USA
    The Consumer Reported Outcome Measures (CROM) Consortium Task Force (TF), consisting of members from seven tobacco manufacturing companies, was formed in 2018 within the Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA). The...
  4. TSRC, Tob. Sci. Res. Conf., 2022, 75, abstr. 50

    Randomized, controlled, open-label, in-clinic study evaluating changes in biomarkers of exposure in adult smokers who switch to on! nicotine pouches for seven days

    RENSCH J.; EDMISTON J.S.; WANG Jingzhu; JIN XIAOHONG; SARKAR M.
    Altria Client Services, Richmond, VA, USA
    Innovative oral tobacco products like on!® nicotine pouches (Test Products) are a rapidly emerging category of tobacco products. Nicotine pouches contain tobacco-derived nicotine, flavors, and other ingredients. The purpose of this study was to...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 01

    Development of consumer-reported outcome measure (CROM) standards for the tobacco industry with respect to psychometric CROM using a consortium-based approach: methodology and scope

    McCAFFREY S.(1) on behalf of the CORESTA CROM Task Force (WG02): AFOLALU E.(2); BLACK R.(1); CHREA C.(2); CURTIN G.(3); GILES L.(4); NISHIHARA D.(4); PRASAD K.(5); SARKAR M.(6); SHETTY M.(5)
    (1) JUUL Labs, Inc., San Francisco, CA, U.S.A.; (2) Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) JT International S.A., Geneva, Switzerland; (5) British American Tobacco, Southampton, U.K.; (6) Altria Client Services, Richmond, VA, U.S.A.
    In November 2018, CORESTA approved the formation of a new Task Force (TF) to establish best practices and guidelines for the integration of consumer-reported outcome measures (CROM) in tobacco regulatory research. The primary objective of the CROM TF...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 02

    Descriptive consumer reported outcome measures and definitions in tobacco and nicotine research: a consensus approach

    WEI L.(1) on behalf of the CROM Task Force: CLERC E.(2); SHETTY M.(3); CHREA C.(2); PRASAD K.(3); SARKAR M.(1)
    (1) Altria Client Services LLC, Richmond, Virginia, U.S.A.; (2) Philip Morris International, Neuchâtel, Switzerland; (3) British American Tobacco, Southampton, U.K.
    The Consumer Reported Outcome Measures (CROM) Consortium Task Force (TF), consisting of academic researchers and members from various tobacco companies, was formed within the Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA) in...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 43

    Quantitative analysis of NNN in plasma: a suitable alternative to urinary determination to assess the exposure to this important toxicant

    PLUYM N.(1); SIBUL F.(1); JIN X.(2); EDMISTON J.(2); SARKAR M.(2); SCHERER G.(1); SCHERER M.(1)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research & Technology, Richmond, VA, U.S.A.
    N-Nitrosonornicotine (NNN) is classified as a Group 1 carcinogen by the International Agency for Research on Cancer. Urinary NNN has often been used as a biomarker of exposure. However, urinary NNN excretion is highly variable, possibly due to...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2021, Online, ST 45

    Meta-analysis study to establish population level estimates of NNAL in smokers and non-smokers

    AYALA-FIERRO F.(1); VERRON T.(2); LIZHNYAK P.(3); FREELAND R.(4); FROST-PINEDA K.(4); ELAMIN A.(5); PRASAD G.L.(4); SARKAR M.(3)
    (1) Juul Labs, Inc, U.S.A.; (2) Imperial Brands, U.K.; (3) Altria Client Services, U.S.A.; (4) RAI Services Company, U.S.A.; (5) Philips Morris International, Switzerland
    The purpose of this research (a project of the CORESTA Biomarkers Sub-Group) was to establish a population level estimate for the biomarker of cigarette smoke exposure, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), to serve as a baseline...